Abstract: Objective　To investigate the application of the combination determination of plasma homocysteine (Hcy) and B-type natriuretic peptide (BNP) in acute myocardial infarction (AMI). Methods　A total of 150 patients with AMI and 135 healthy subjects were enrolled. The levels of plasma BNP and Hcy were determined after admission and drug thrombolysis or percutaneous coronary intervention (PCI) in patients with AMI. The levels of plasma BNP and Hcy were compared between 51 patients with cardiovascular events and 99 patients without cardiovascular events during hospitalization and follow-up.  Results　The levels of plasma BNP[(594.38±167.58)pg/mL] and Hcy[(37.6±11.44)μmol/L] in patients with AMI were higher than those in healthy controls[(56.32±28.79)pg/mL and (7.62±3.18)μmol/L](P＜0.05). After admission and drug thrombolysis or PCI， the levels of plasma BNP[(256.94±118.55) pg/mL or (78.03±11.24)pg/mL] and Hcy[(16.47±7.24)μmol/L or (10.33±6.09)μmol/L] in patients with AMI were lower than those before admission and drug thrombolysis or PCI[(494.37±183.63)pg/mL and  (35.53±8.12)μmol/L](P＜0.05).The levels of patients with cardiovascular events[BNP(609.15±287.37)pg/mL and Hcy (39.5±12.61) μmol/L] were higher than those without cardiovascular events[BNP(326.85±134.24)pg/mLand Hcy (14.56±7.12)μmol/mL](P＜0.05). Conclusions　The plasma BNP and Hcy are related to AMI. Plasma BNP and Hcy may be as application parameters in AMI.

Key words: B-type natriuretic peptide, Homocysteine, Acute myocardial infarction, Diagnosis, Prognosis